Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve functional outcomes of patients suffering from age-related diseases, presented results from its recent clinical trials with RuvembriTM at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference held March 3-6, 2024 in Orlando, United States.